Vertex and CRISPR Therapeutics Present New Data of CTX001 from 22 Patients with TDT and SCD at EMA 2021
Shots:
- The ongoing two P-I/ II studies- CLIMB-Thal-111 & CLIMB-SCD-121 evaluating CTX001 in 45 patients with a follow-up of ~2yrs. after infusion aged 18-35yrs to treat transfusion-dependent beta-thalassemia & sickle cell disease
- The results from 22 patients with a follow-up of >3 mos.- i.e 15 patients with TDT are transfusion-free after CTX001 infusion @ follow-up of 4 to 26 mos.- improvement in total hemoglobin & fetal hemoglobin
- Remaining 7 patients with SCD showed free of VOC's after CTX001 infusion @ follow-up of 5 to 22 mos.- improvements in total hemoglobin & fetal hemoglobin levels. Additioanlly- 5 patients with TDT & 2 patients with SCD with follow-up of > 1yr. showed a stable & durable response
| Ref: Business Wire | Image: Vertex
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com